Jorien van der Schaft

Dupilumab is very effective in a large cohort of difficult‐to‐treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry

Lieneke F.M. Ariëns, Jorien van der Schaft, Daphne S. Bakker et al. · Allergy · 2019 · 149 citations · Full text

Life Sciences, Dermatology, Pharmacotherapy +15

Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers

Daphne S. Bakker, Stefan Nierkens, Edward F. Knol et al. · Journal of Allergy and Clinical Immunology · 2020 · 124 citations · Full text

Medicine, Dermatology, Immunology +16

Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry

Lieneke F.M. Ariëns, Jorien van der Schaft, Lotte S. Spekhorst et al. · Journal of the American Academy of Dermatology · 2020 · 91 citations · Full text

Life Sciences, Dermatology, Immunology +12

Drug survival for ciclosporin A in a long-term daily practice cohort of adult patients with atopic dermatitis

Jorien van der Schaft, Klaziena Politiek, J.M.P.A. van den Reek et al. · British Journal of Dermatology · 2015 · 77 citations

Medicine, Dermatology, Pharmacotherapy +17

Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment

Lieneke F.M. Ariëns, Kirsten van Nimwegen, M Shams et al. · Acta Dermato Venereologica · 2019 · 75 citations · Full text

Pharmacy, Dermatology, Pharmacoeconomics +17